The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2020 | CAR-T and antibody developments: aggressive lymphomas
Nilanjan Ghosh MD, PhD, of Levine Cancer Institute, Charlotte, NC, discusses novel developments in cellular and bispecific antibody therapies for aggressive lymphomas. Specifically discussed is AUTO3, a CAR-T cell therapy targeting CD19 and CD22, that has been investigated in combination with pembrolizumab. Furthermore, Dr Ghosh highlights glofitamab, an anti-CD20/CD3 bispecific antibody evaluated in relapsed/refractory B-cell non-Hodgkin’s lymphoma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
